National Jewish Health

COPD GENE - GENETIC EPIDEMIOLOGY OF COPD - TASK AREA A: YEAR 4 - AUGUST 10, 2026 - AUGUST 09, 2027

THE SUB PI AND OTHER BWH INVESTIGATORS WILL PARTICIPATE IN TASK A FOR ALL FIVE YEARS OF THE COPDGENE PHASE 4 PROJECT AND WILL PROVIDE KEY CONTRIBUTIONS TO BOTH SPECIFIC AIMS OF THE TECHNICAL PROPOSAL. HE WILL LEAD THE BWH COMPONENT OF THE COPDGENE ADMINISTRATIVE CENTER AS WELL AS THE GENETIC ANALYSIS CENTER. THE OTHER BWH INVESTIGATOR WILL DIRECT THE BIOINFORMATICS CENTER, WHICH WILL PERFORM OMICS DATA ANALYSIS WITH STATISTICAL, MACHINE LEARNING, AND NETWORK APPROACHES. SAN JOSE ESTEPAR WILL LEAD THE BWH COMPONENT OF THE COPDGENE IMAGING CENTER, WHICH WILL FOCUS ON LOCAL EMPHYSEMA PROGRESSION AND COMORBIDITY (CARDIAC, PULMONARY VASCULAR, AND PECTORALIS MUSCLE) MEASURES IN COPDGENE CT SCANS. NWH INVESTIGATORS WILL CONTINUE TO CO-LEAD THE COPDGENE SUBTYPING CENTER. THE COPDGENE BIOREPOSITORY STAFF AT BWH WILL WORK WITH BWH INVESTIGATORS TO PROVIDE QUALITY-CONTROLLED GENOMIC AND MOLECULAR DATA FROM COPDGENE BIOSPECIMENS COLLECTED DURING ALL STUDY VISITS. THE LEAD PI AND THE BWH CO-INVESTIGATORS WILL PARTICIPATE IN MULTIPLE WEEKLY CALLS AND REGULAR COPDGENE INVESTIGATOR MEETINGS TO DISCUSS TASK A ACTIVITIES.

THE SUB SITE PIS AT THE UNIVERSITY OF COLORADO DENVER (ANSCHUTZ CAMPUS) AND THEIR TEAM ARE THE EPIDEMIOLOGY CENTER FOR COPDGENE. THIS EPIDEMIOLOGY CENTER IS A CRITICAL COMPONENT OF COPDGENE AND SHARES RESPONSIBILITY FOR COMPLETION OF THE GENERAL SPECIFIC AIMS OF THIS STUDY. THIS INCLUDES PARTICIPATION IN THE FOLLOWING GROUPS: CLINICAL EPIDEMIOLOGY, COVID-19, CLINICAL TRANSLATION, COPDGENE 2024, ANCILLARY STUDIES AND PUBLICATIONS, AND THE EXECUTIVE COMMITTEE. THIS GROUP IS RESPONSIBLE FOR COPDGENE DATA ANALYSIS IN THE FIELD OF EPIDEMIOLOGY. A PRIMARY FOCUS OF THIS EPIDEMIOLOGY IS REFINEMENT OF THE AIRWAY-PREDOMINANT AND EMPHYSEMA-PREDOMINANT SUBTYPES OF COPD. THIS IS A CENTRAL GOAL OF COPDGENE AND INCLUDES ANALYSIS OF DIFFERENTIAL DISEASE PROGRESSION AND MORTALITY EXPERIENCED BY THESE CLINICALLY RELEVANT SUBTYPES. THE TEAM WILL USE ‘OMICS DATA TO IDENTIFY GENETIC AND BIOLOGICAL DETERMINANTS FOR THE SUSCEPTIBILITY OF THE DIFFERENT SUBTYPES OF COPD. THE TEAM WILL ALSO HAVE RESPONSIBILITY TO IDENTIFY DISTINCT TREATMENT PATTERNS, INCLUDING COMORBIDITIES, WHICH INFLUENCE THE DEVELOPMENT ANDPROGRESSION OF AIRWAY-PREDOMINANT AND EMPHYSEMA-PREDOMINANT SUBTYPES. THE TEAM WILL ALSO CONTINUE ITS WORK IDENTIFYING SMOKING PATTERNS AND BEHAVIOR AND IDENTIFY PATHOPHYSIOLOGIC AND SOCIAL INFLUENCES ON THE AIRWAY-PREDOMINANT AND EMPHYSEMA-PREDOMINANT SUBTYPES OF COPD.

NATIONAL JEWISH HEALTH-STAND ALONE-ITEM LEVEL-EMPLOYEE BENEFITS, BUSINESS INSURANCE AND ANCILLARY SERVICES (PENSION, RETIREE MEDICAL, ACTUARIAL, ETC.)